Manufacturing Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb PharmaTimesAragen scales Daretabart to commercial-ready production following rapid 9month tech transferRead full story pharminent June 2, 2026 (Last updated: June 4, 2026) PharmaTimes Aragen scales Daretabart to commercial-ready production following rapid 9month tech transfer Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: The 340B Contract Pharmacy Market in 2026: A Maturing Industry Dominated by Big Chains and PBMsNext: BMS secures FDA acceptance for Camzyos sNDA Related Stories Manufacturing AsymBio to secure $184m to support growth in biologics manufacturing pharminent August 5, 2026 Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply pharminent July 31, 2026 Manufacturing GSK Cambridge Move Signals Shift in Drug Scale-Up Strategy pharminent July 29, 2026
